University of California, San Francisco.
Arthritis Rheumatol. 2015 May;67(5):1305-13. doi: 10.1002/art.39026.
There is a need to determine which response measures in lupus nephritis trials are most predictive of good long-term renal function. We used data from the Euro-Lupus Nephritis Trial to evaluate the performance of proteinuria, serum creatinine (Cr), and urinary red blood cells (RBCs) as predictors of good long-term renal outcome.
Patients from the Euro-Lupus Nephritis Trial with proteinuria, serum Cr, and urinary RBC measurements at 3, 6, or 12 months and with a minimum of 7 years of followup were included (n = 76). We assessed the ability of these clinical biomarkers at 3, 6, and 12 months after randomization to predict good long-term renal outcome (defined as a serum Cr value ≤1.0 mg/dl) at 7 years. Receiver operating characteristic curves were generated to assess parameter performance at these time points and to select the best cutoff for individual parameters. Sensitivity and specificity were calculated for the parameters alone and in combination.
A proteinuria value of <0.8 gm/day at 12 months after randomization was the single best predictor of good long-term renal function (sensitivity 81% and specificity 78%). The addition of serum Cr to proteinuria as a composite predictor did not improve the performance of the outcome measure; addition of urinary RBCs as a predictor significantly decreased the sensitivity to 47%.
This study demonstrates that the level of proteinuria at 12 months is the individual best predictor of long-term renal outcome in patients with lupus nephritis. Inclusion of urinary RBCs as part of a composite outcome measure actually undermined the predictive value of the trial data. We therefore suggest that urinary RBCs should not be included as a component of clinical trial response criteria in lupus nephritis.
需要确定狼疮肾炎试验中的哪些反应措施最能预测长期肾功能良好。我们使用来自 Euro-Lupus Nephritis Trial 的数据,评估蛋白尿、血清肌酐 (Cr) 和尿红细胞 (RBC) 作为预测长期肾脏预后的指标的表现。
纳入在随机分组后 3、6 或 12 个月有蛋白尿、血清 Cr 和尿 RBC 测量值且随访时间至少 7 年的 Euro-Lupus Nephritis Trial 患者 (n=76)。我们评估这些临床生物标志物在随机分组后 3、6 和 12 个月时预测 7 年时良好长期肾脏结局(定义为血清 Cr 值≤1.0 mg/dl)的能力。生成受试者工作特征曲线,以评估这些时间点的参数表现,并为单个参数选择最佳截止值。单独和联合使用参数计算敏感性和特异性。
随机分组后 12 个月时蛋白尿<0.8 gm/天是长期肾功能良好的单一最佳预测指标(敏感性 81%,特异性 78%)。将血清 Cr 添加到蛋白尿作为复合预测因子并不能提高结局测量的性能;将尿 RBC 添加为预测因子会显著降低敏感性至 47%。
这项研究表明,狼疮肾炎患者 12 个月时的蛋白尿水平是长期肾脏结局的最佳个体预测指标。将尿 RBC 作为复合结局测量的一部分实际上削弱了试验数据的预测价值。因此,我们建议不应将尿 RBC 纳入狼疮肾炎临床试验的反应标准。